Download PDF
Semin intervent Radiol 2023; 40(02): 167-171
DOI: 10.1055/s-0043-57263
Review Article

Below-the-Knee Stents and Scaffolds: A Comprehensive Review

Farnaz Dadrass
1   Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
,
Sahitya C. Raja
2   Department of Vascular and Interventional Radiology, Rush University Medical Center, Chicago, Illinois
,
Robert Lookstein
1   Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Below-the-knee intervention of chronic limb-threatening ischemia is an area of increasing interest. Due to lower morbidity and possibly better clinical outcomes, endovascular techniques have become increasingly important in this patient population many of who have limited surgical options. This article serves as a review of existing stent and scaffolding devices utilized for infrapopliteal disease. The authors will additionally discuss current indications and review studies that are investigating novel materials used in treating infrapopliteal arterial disease.

Keywords

interventional radiology - endovascular intervention - stent - angioplasty - ischemia - chronic limb-threatening ischemia


Publication History

Article published online:
16 June 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Conte MS, Bradbury AW, Kolh P. et al; GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019; 58 (1S): S1-S109
    CrossrefPubMedGoogle Scholar
  • 2 Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 2016; 51 (03) 395-403
    CrossrefPubMedGoogle Scholar
  • 3 Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull 2013; 106 (01) 193-211
    CrossrefPubMedGoogle Scholar
  • 4 Giaquinta A, Vincenzo A, De Marco E, Veroux M, Veroux P. Everolimus-eluting stent for patients with critical limb ischemia and infrapopliteal arterial occlusive disease. Vasc Endovascular Surg 2017; 51 (02) 60-66
    CrossrefPubMedGoogle Scholar
  • 5 Biondi-Zoccai GGL, Sangiorgi G, Lotrionte M. et al. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther 2009; 16 (03) 251-260
    CrossrefPubMedGoogle Scholar
  • 6 Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. J Am Coll Cardiol 2010; 55 (15) 1580-1589
    CrossrefPubMedGoogle Scholar
  • 7 Spreen MI, Martens JM, Hansen BE. et al. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv 2016; 9 (02) e002376
    CrossrefPubMedGoogle Scholar
  • 8 Bosiers MJ, Deloose K, Peeters P. et al. Outcome of a drug-eluting stent in longer below-the-knee lesions in patients with critical limb ischemia. J Cardiovasc Surg (Torino) 2017; 58 (01) 49-54
    PubMedGoogle Scholar
  • 9 Waugh J, Wagstaff AJ. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 2004; 4 (04) 257-268
    PubMedGoogle Scholar
  • 10 Scheinert D, Katsanos K, Zeller T. et al; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012; 60 (22) 2290-2295
    CrossrefPubMedGoogle Scholar
  • 11 Rastan A, Brechtel K, Krankenberg H. et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol 2012; 60 (07) 587-591
    CrossrefPubMedGoogle Scholar
  • 12 Taeymans K, Bosiers M, Deloose K. et al. One-year outcome of the everolimus-eluting, balloon-expandable Promus Element and Promus Element Plus stent in the treatment of below-the-knee lesions in CLI patients. J Cardiovasc Surg (Torino) 2020; 61 (04) 445-450
    PubMedGoogle Scholar
  • 13 Bosiers M, Scheinert D, Peeters P. , et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg 2012; 55 (02) 390-398 DOI: 10.1016/j.jvs.2011.07.099.
    CrossrefPubMed
  • 14 Bosiers M, Callaert J, Keirse K. et al. One-year outcomes of the paclitaxel-eluting, self-expanding Stentys stent system in the treatment of infrapopliteal lesions in patients with critical limb ischemia. J Endovasc Ther 2017; 24 (03) 311-316
    CrossrefPubMedGoogle Scholar
  • 15 van Overhagen H. SAVAL Primary Results of the Randomized Trial of DES vs PTA in Infrapopliteal Arteries. Barcelona, Spain: CIRSE; 2022
    Google Scholar
  • 16 Brodmann M, Wissgott C, Holden A. et al. Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study. Catheter Cardiovasc Interv 2018; 92 (01) 96-105
    CrossrefPubMedGoogle Scholar
  • 17 Ali ZA, Serruys PW, Kimura T. et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet 2017; 390 (10096): 760-772
    CrossrefPubMedGoogle Scholar
  • 18 Chevalier B, Cequier A, Dudek D. et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention 2018; 13 (13) 1561-1564
    CrossrefPubMedGoogle Scholar
  • 19 Wykrzykowska JJ, Kraak RP, Hofma SH. et al; AIDA Investigators. Bioresorbable scaffolds versus metallic stents in routine PCI. N Engl J Med 2017; 376 (24) 2319-2328
    CrossrefPubMedGoogle Scholar
  • 20 Jinnouchi H, Torii S, Sakamoto A, Kolodgie FD, Virmani R, Finn AV. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat Rev Cardiol 2019; 16 (05) 286-304
    CrossrefPubMedGoogle Scholar
  • 21 Fan W, Tan J, Li L. et al. Efficacy and safety of absorb everolimus-eluting bioresorbable vascular scaffold in peripheral artery disease: a single-arm meta-analysis. J Endovasc Ther 2022; 152660282210918: 15 266028221091899
    PubMedGoogle Scholar
  • 22 Ward TJ, Lookstein RA. Drug-eluting stents in the below-knee circulation for patients with critical limb ischemia: when and where. Tech Vasc Interv Radiol 2014; 17 (03) 177-182
    CrossrefPubMedGoogle Scholar